LOGIN  |  REGISTER
Compass Therapeutics

Kovo HealthTech Announces Departure of Greg Noble as CEO and Appointment of Brenner Adams as Interim Successor

July 09, 2024 | Last Trade: C$0.03 0.00 0.00

Vancouver, British Columbia--(Newsfile Corp. - July 9, 2024) - Kovo HealthTech Corporation (TSXV: KOVO) ("Kovo" or the "Company") today announced that Mr. Greg Noble has stepped down as Chief Executive Officer and that the Board of Directors has selected Brenner Adams to succeed Mr. Noble as interim CEO.

During his tenure, Mr. Noble led the Company's public listing on the TSX Venture Exchange and oversaw several acquisitions and operational efficiencies that grew the company from $1.7M to $10.0M from Fiscal 2019 to Fiscal 2023. Whereas Mr. Noble is departing as CEO, he has signed a long-term contract to provide M&A consulting services for the Company. "KOVO is now well positioned as an acquisition engine for continued growth into the future and I look forward to assisting the team in finding new and valuable RCM targets to purchase," stated Noble.

Stepping into the CEO position, Brenner Adams is an international executive with a robust background in business development, marketing, and product leadership who significantly impacted the healthcare industry during his tenure as Chief Innovation Officer at Med USA, a Revenue Cycle Management and Credentialing Services company. Additionally, Adams helped launch two successful spinoffs, with one securing public state funding in the process. The Board believes Adams is well-equipped to ensure a seamless transition and continue the company's aggressive growth trajectory.

"We extend our gratitude to Greg for his leadership and unwavering dedication during his tenure as CEO and we are confident in Brenner's ability to continue the Company's growth and excellence in all aspects during this transitional period and beyond," said Peter Bak, Kovo's Chairman of the Board.

About Kovo HealthTech Corporation

Kovo HealthTech Corporation is a growing healthcare technology company that specializes in Billing-as-a-Service offering SaaS-style recurring revenue contracts and software for more than 2250 US healthcare providers. Kovo helps healthcare providers digitally track and manage complex patient care registration, services, billing and payments in a seamless way. Currently, through its clients, Kovo processes over $250 million CAD ($200M USD) in annual billing transactions for more than 3.5 million patients. By offering effective billing practices, Kovo helps healthcare practitioners get paid so they can focus on offering quality care. To learn more about Kovo and to keep up-to-date on Kovo news, visit www.kovo.co.

For more information:
Peter Bak, Board Chair
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-866-558-6777

Forward-Looking Information

This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to future acquisitions and relative growth of the Company. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Corporation. Although management of the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Corporation relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company's ability to raise future capital, the Company's ability to meet the terms of its current debt obligations and to repay its indebtedness, the Corporation's ability to efficiently and successfully develop new opportunities, failure to identify future transactional counter-parties . Accordingly, readers should not place undue reliance on the forward‐looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB